{
    "clinical_study": {
        "@rank": "97289", 
        "arm_group": [
            {
                "arm_group_label": "Detemir", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "NPH", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Africa, Europe and  Oceania. The aim of this trial is to\n      investigate whether insulin detemir combined with insulin aspart compared to NPH insulin\n      combined with insulin aspart could reduce the frequency of hypoglycaemic episodes whilst\n      maintaining the same degree of glycaemic control subjects with type 1 diabetes."
        }, 
        "brief_title": "Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "November 2002", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Hypoglycemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes\n\n          -  Fasting c-peptide below lower limit of normal fasting range\n\n          -  Duration of type 1 diabetes for at least 12 months\n\n          -  Current treatment: Basal - bolus regimen for at least 4 months with intermediate or\n             long-acting insulin once, twice or three times daily as basal insulin and 3-4 premeal\n             insulin aspart or lispro injections\n\n          -  HbA1c maximum 9.0% (using Biorad Variant method)\n\n          -  Able and willing to perform self-monitoring of blood glucose\n\n          -  Basal insulin requirement at least 30% of the total daily insulin dose\n\n          -  BMI (body Mass Index) maximum 35 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Proliferative retinopathy or maculopathy requiring acute treatment\n\n          -  Total daily insulin dose above 1.4 IU/kg/day\n\n          -  Known unawareness of hypoglycaemia\n\n          -  Impaired hepatic function\n\n          -  Impaired renal function\n\n          -  Cardiac problems\n\n          -  Uncontrolled, treated/untreated hypertension\n\n          -  Known or suspected allergy to trial product or related products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "131", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697657", 
            "org_study_id": "NN304-1375"
        }, 
        "intervention": [
            {
                "arm_group_label": "Detemir", 
                "description": "Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2", 
                "intervention_name": "insulin detemir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NPH", 
                "description": "Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2", 
                "intervention_name": "insulin NPH", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Detemir", 
                    "NPH"
                ], 
                "description": "Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin", 
                "Hypoglycemic Agents", 
                "Insulin, NPH", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 28, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Camperdown", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2050"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zagreb", 
                        "country": "Croatia", 
                        "zip": "10 000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u00c5rhus C", 
                        "country": "Denmark", 
                        "zip": "8000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perugia", 
                        "country": "Italy", 
                        "zip": "06126"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "state": "Western Cape", 
                        "zip": "7925"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Link\u00f6ping", 
                        "country": "Sweden", 
                        "zip": "581 85"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Croatia", 
                "Denmark", 
                "Italy", 
                "South Africa", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Open Label, Cross-over, Multi-centre, Multinational Trial Comparing the Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir and NPH Insulin in Well Controlled Subjects With Type 1 Diabetes on a Basal-bolus Regimen", 
        "overall_official": [
            {
                "affiliation": "Novo Nordisk A/S", 
                "last_name": "Bente Tronier", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Novo Nordisk A/S", 
                "last_name": "Malene Bording Kr\u00fcger", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Croatia: Ministry of Health and Social Care", 
                "Denmark: Danish Medicines Agency", 
                "Italy: National Institute of Health", 
                "South Africa: Medicines Control Council", 
                "Sweden: Medical Products Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of total self-recorded hypoglycaemic episodes", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697657"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of total major hypoglycaemic episodes", 
                "safety_issue": "No"
            }, 
            {
                "measure": "HbA1c (glycosylated haemoglobin)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "8-point plasma glucose profiles", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Serum glucose profiles", 
                "safety_issue": "No"
            }, 
            {
                "measure": "72-hours glucose profile", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Within-subject variation in home-measured fasting plasma glucose", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}